Published on

November 18, 2026

Last updated on

November 18, 2026

Beijing MPA Clarifies Electronic Customs Clearance Pilot for Imported Drugs

On October 23, 2026, the Beijing Municipal Medical Products Administration (Beijing MPA) published an implementation notice providing further guidance on the electronic customs clearance pilot for imported drugs, including medicinal materials, at Beijing ports. The pilot was launched on September 21, 2026, following the National Medical Products Administration (NMPA) and General Administration of Customs (GACC) Announcement No.91 of 2026.

The pilot enables the electronic issuance of import customs clearance documents without changing existing drug requirements. No specific end date has been announced, and implementation remains subject to subsequent regulatory adjustments.

Previously, although import filing applications and approvals were processed online, companies still needed to collect paper customs clearance documents from the relevant administrative office. Under the pilot, reporting entities can now download and print the electronic documents directly through China’s International Trade Single Window platform following approval:

  • Import Drug Customs Clearance Form
  • Import Drug Port Inspection Notice

Both documents have the same legal effect as their paper equivalents, which remain valid throughout the pilot period. The electronic customs clearance form includes an official electronic seal and a QR code that enables verification of key document information and its validity.

Key Requirements for Participating Companies

The pilot does not change the underlying requirements for import filings. Reporting entities must continue to meet existing obligations for certificate verification, supporting documentation and recordkeeping.

Under China's Measures for the Administration of Drug Imports, the authenticity of relevant drug registration certificates and import permits must continue to be verified. To facilitate this process, reporting entities may upload electronic copies of the relevant certificates through the "Attachment Information" section of the International Trade Single Window platform.

Reporting entities must also ensure that:

  • All submitted materials are authentic, complete and legible
  • Supporting certificates are available for authenticity verification when required
  • Electronic customs clearance documents are properly used and retained in accordance with applicable requirements

Final Thoughts

For foreign pharmaceutical companies importing products through Beijing ports, the pilot offers an opportunity to streamline administrative procedures by reducing reliance on physical document collection. Companies should coordinate with their Chinese importers and reporting entities to ensure they are familiar with the updated electronic document issuance and retrieval procedures.

Companies should ensure their Chinese partners:

  • Have access to the relevant registration certificates and import permits and can provide them for authenticity verification when required
  • Know how to use the International Trade Single Window to upload supporting certificates and submit accurate, complete and legible documentation
  • Can download and retain electronic customs clearance documents, understand the updated platform procedures and know where to seek assistance if issues arise

Companies should also ensure supporting documents are up to date and consistent with the products being imported. Cisema can help review import documentation and coordinate with Chinese partners to ensure filings meet applicable requirements.

For support with pharmaceutical import documentation, customs clearance requirements and regulatory compliance in China, contact Cisema today.

Further Information

References

Connect with Cisema

With more than 20 years of experience and a team of over 100 specialists, Cisema helps global companies achieve compliance across Asia Pacific with confidence and accelerate market entry.

Talk to an Expert
Explore Whitepapers

Stay Informed with Monthly News and Analysis

Stay informed with the latest regulatory changes, expert insights, and market opportunities across APAC, delivered straight to your inbox.

Sign Up for Newsletter

Contact Our Consultants & Discover How We Can Support You

Let Cisema help turn your plans into reality.

Request Proposal